Association of Mac‐2‐binding protein glycosylation isomer level with nutritional status in chronic liver disease

Mac‐2‐binding protein glycosylation isomer (M2BPGi) was recently identified as a serum glycobiomarker for liver fibrosis. However, the relationship between M2BPGi and malnutrition in patients with chronic liver disease (CLD) is unknown. We aimed to evaluate whether M2BPGi could be a surrogate marker for malnutrition in patients with CLD.

[1]  Limei Qu,et al.  Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C , 2017, BMC Gastroenterology.

[2]  T. Fujiwara,et al.  Preoperative Controlling Nutritional Status (CONUT) Score for Assessment of Prognosis Following Hepatectomy for Hepatocellular Carcinoma , 2017, World Journal of Surgery.

[3]  M. Merli,et al.  A practical approach to nutritional screening and assessment in cirrhosis , 2017, Hepatology.

[4]  R. Takata,et al.  Serum Wisteria floribunda agglutinin‐positive Mac‐2‐binding protein for patients with chronic hepatitis B and C: a comparative study , 2016, Journal of viral hepatitis.

[5]  S. Kakinuma,et al.  Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy , 2016, Hepatology International.

[6]  R. Takata,et al.  Clinical significance of serum Wisteria floribunda agglutinin positive Mac‐2‐binding protein level and high‐sensitivity C‐reactive protein concentration in autoimmune hepatitis , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[7]  R. Takata,et al.  Impact of serum Wisteria floribunda agglutinin positive Mac‐2‐binding protein and serum interferon‐γ‐inducible protein‐10 in primary biliary cirrhosis , 2016, Hepatology research : the official journal of the Japan Society of Hepatology.

[8]  J. Hayashi,et al.  Serum WFA+‐M2BP is a non‐invasive liver fibrosis marker that can predict the efficacy of direct‐acting anti‐viral‐based triple therapy for chronic hepatitis C , 2016, Alimentary pharmacology & therapeutics.

[9]  M. Shimizu,et al.  Impact of serum glycosylated Wisteria floribunda agglutinin positive Mac‐2 binding protein levels on liver functional reserves and mortality in patients with liver cirrhosis , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[10]  M. Kurosaki,et al.  Wisteria floribunda agglutinin positive human Mac‐2‐binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[11]  H. Narimatsu.  Development of M2BPGi: a novel fibrosis serum glyco-biomarker for chronic hepatitis/cirrhosis diagnostics , 2015, Expert review of proteomics.

[12]  R. Flisiak,et al.  Hyaluronic acid concentration in liver diseases , 2015, Clinical and Experimental Medicine.

[13]  Y. Imai,et al.  Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fibrosis stage of non-alcoholic fatty liver disease , 2015, Journal of Gastroenterology.

[14]  A. Kuno,et al.  Serum Wisteria Floribunda Agglutinin-Positive Mac-2 Binding Protein Values Predict the Development of Hepatocellular Carcinoma among Patients with Chronic Hepatitis C after Sustained Virological Response , 2015, PloS one.

[15]  A. Kuno,et al.  Clinicopathological characteristics and diagnostic performance of Wisteria floribunda agglutinin positive Mac-2-binding protein as a preoperative serum marker of liver fibrosis in hepatocellular carcinoma , 2015, Journal of Gastroenterology.

[16]  Lunan Yan,et al.  Comparison of diagnostic accuracy of aspartate aminotransferase to platelet ratio index and fibrosis‐4 index for detecting liver fibrosis in adult patients with chronic hepatitis B virus infection: A systemic review and meta‐analysis , 2015, Hepatology.

[17]  O. Tanrıverdi.  A discussion of serum albumin level in advanced-stage hepatocellular carcinoma: a medical oncologist’s perspective , 2014, Medical Oncology.

[18]  A. Kuno,et al.  Elevated serum levels of Wisteria floribunda agglutinin-positive human Mac-2 binding protein predict the development of hepatocellular carcinoma in hepatitis C patients , 2014, Hepatology.

[19]  Y. Osaki,et al.  Clinical significance of therapy using branched‐chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma , 2014, Hepatology research : the official journal of the Japan Society of Hepatology.

[20]  H. Parsian,et al.  Hyaluronic Acid: From Biochemical Characteristics to its Clinical Translation in Assessment of Liver Fibrosis , 2013, Hepatitis monthly.

[21]  A. Torre,et al.  Nutritional assessment and treatment of patients with liver cirrhosis. , 2013, Nutrition.

[22]  A. Kuno,et al.  Reconstruction of a robust glycodiagnostic agent supported by multiple lectin‐assisted glycan profiling , 2013, Proteomics. Clinical applications.

[23]  Marc Diltoer,et al.  Introducing a new generation indirect calorimeter for estimating energy requirements in adult intensive care unit patients: feasibility, practical considerations, and comparison with a mathematical equation. , 2013, Journal of critical care.

[24]  A. Moorman,et al.  Noninvasive serum fibrosis markers for screening and staging chronic hepatitis C virus patients in a large US cohort. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  R. Butterworth,et al.  The nutritional management of hepatic encephalopathy in patients with cirrhosis: International society for hepatic encephalopathy and nitrogen metabolism consensus , 2013, Hepatology.

[26]  A. Kuno,et al.  A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis , 2013, Scientific Reports.

[27]  P. Rathi,et al.  Nutritional status and prognosis in cirrhotic patients. , 2012, Tropical gastroenterology : official journal of the Digestive Diseases Foundation.

[28]  M. Karsdal,et al.  Molecular Serum Markers of Liver Fibrosis , 2012, Biomarker insights.

[29]  P. Siersema,et al.  Protein energy malnutrition predicts complications in liver cirrhosis , 2011, European journal of gastroenterology & hepatology.

[30]  T. Sawai,et al.  Quantitative measurement of serum hyaluronic acid molecular weight in rheumatoid arthritis patients and the role of hyaluronidase , 2011, International journal of rheumatic diseases.

[31]  T. Kawaguchi,et al.  Branched‐chain amino acids as pharmacological nutrients in chronic liver disease , 2011, Hepatology.

[32]  S. Rajagopalan,et al.  Association between markers of collagen turnover, arterial stiffness and left ventricular hypertrophy in chronic kidney disease (CKD): the Renal Research Institute (RRI)-CKD study. , 2011, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[33]  Ying Sun,et al.  Performance of the aspartate aminotransferase‐to‐platelet ratio index for the staging of hepatitis C‐related fibrosis: An updated meta‐analysis , 2011, Hepatology.

[34]  H. Moriwaki,et al.  Indirect calorimetry and anthropometry to estimate energy metabolism in patients with liver cirrhosis. , 2010, Journal of nutritional science and vitaminology.

[35]  C. Ker,et al.  Albumin and prealbumin may predict retinol status in patients with liver cirrhosis. , 2008, Hepato-Gastroenterology.

[36]  M. Kurosaki,et al.  External validation of FIB‐4: Diagnostic accuracy is limited in elderly populations , 2007, Hepatology.

[37]  J. Montaner,et al.  Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection , 2006, Hepatology.

[38]  D. Rockey,et al.  Noninvasive measures of liver fibrosis , 2006, Hepatology.

[39]  P. Gibson,et al.  Mechanisms by which food intake elevates circulating levels of hyaluronan in humans , 2005, Journal of internal medicine.

[40]  G. Leandro,et al.  Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. , 2003, Journal of hepatology.

[41]  J. Kalbfleisch,et al.  A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C , 2003, Hepatology.

[42]  J. Iredale,et al.  Is liver fibrosis reversible? , 2000, Gut.

[43]  P. Gibson,et al.  Effects of eating on plasma hyaluronan in patients with cirrhosis: Its mechanism and influence on clinical interpretation , 1998, Journal of gastroenterology and hepatology.

[44]  M. Yonemaru,et al.  Clinical evaluation of serum type IV collagen 7S in idiopathic pulmonary fibrosis , 1996, Respirology.

[45]  H. Kawasaki,et al.  Relationship between serum and hepatic 7S fragments of type IV collagen in chronic liver disease , 1996, Hepatology.

[46]  H. Kawasaki,et al.  Serum type III procollagen peptide, type IV collagen 7S domain, central triple‐helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: Relationship to liver histology , 1994, Hepatology.

[47]  J. Ladero,et al.  Liver fibrosis. , 2018, The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology.

[48]  M. Shimizu,et al.  Sarcopenia impairs prognosis of patients with liver cirrhosis. , 2015, Nutrition.

[49]  Y. Maehara,et al.  A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA+-M2BP), for assessing liver fibrosis , 2014, Journal of Gastroenterology.

[50]  J Ignacio de Ulíbarri,et al.  CONUT: a tool for controlling nutritional status. First validation in a hospital population. , 2005, Nutricion hospitalaria.